Published in Transfusion on September 01, 2003
Retrovirus Epidemiology Donor Study I (REDS I) | NCT00005278
Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer (2010) 2.68
Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. Cancer Lett (2011) 1.71
Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2007) 1.28
Estimation of sensitivity and specificity of several Trypanosoma cruzi antibody assays in blood donors in Argentina. Transfusion (2009) 1.22
Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J Infect Dis (2009) 1.22
Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection. J Clin Microbiol (2006) 1.21
Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma belt". Int J Cancer (2010) 1.18
The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability. Transfus Med Rev (2012) 1.14
Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. Am J Epidemiol (2008) 1.11
Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis. J Clin Microbiol (2006) 1.10
Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. J Immunol Methods (2010) 1.09
Development of an immunofluorescence assay using recombinant proteins expressed in insect cells to screen and confirm presence of human herpesvirus 8-specific antibodies. Clin Vaccine Immunol (2008) 1.03
Human herpesvirus 8--a novel human pathogen. Virol J (2005) 1.00
Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. AIDS (2013) 0.95
Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray. J Infect Dis (2011) 0.93
The viral etiology of AIDS-associated malignancies. Adv Pharmacol (2008) 0.89
Human herpesvirus 8 seroprevalence, China. Emerg Infect Dis (2012) 0.89
Epidemiology and genetic variability of HHV-8/KSHV in Pygmy and Bantu populations in Cameroon. PLoS Negl Trop Dis (2014) 0.86
Prevalence of human herpesvirus 8 and hepatitis C virus in a rural community with a high risk for blood-borne infections in central China. Clin Microbiol Infect (2011) 0.85
Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study. Br J Cancer (2011) 0.84
Seroprevalence of human herpesvirus-8 in HIV-1 infected and uninfected individuals in Cameroon. Viruses (2013) 0.83
Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS Pathog (2014) 0.83
Epidemiology and transmission of Kaposi's sarcoma-associated herpesvirus. Viruses (2014) 0.80
The T-Cell Immune Response against Kaposi's Sarcoma-Associated Herpesvirus. Adv Virol (2011) 0.80
A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago. Infect Agent Cancer (2011) 0.80
Recreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men. AIDS Res Hum Retroviruses (2009) 0.78
Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control (2014) 0.77
Chromatinization of the KSHV Genome During the KSHV Life Cycle. Cancers (Basel) (2015) 0.77
Human herpesvirus 8 seroprevalence among Tobago women and the role of sexual lifestyle behavior. J Med Virol (2009) 0.77
Non-detection of human herpesvirus 8 (HHV-8) DNA in HHV-8-seropositive blood donors from three Brazilian regions. PLoS One (2011) 0.76
Development of whole-virus multiplex luminex-based serological assays for diagnosis of infections with kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 homologs in macaques. Clin Vaccine Immunol (2013) 0.76
Elevated serum PSA Is associated with human herpesvirus 8 infection and increased circulating cytokine levels in men from tobago. Prostate (2017) 0.75
Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus. PLoS One (2016) 0.75
No Evidence of Human Herpesvirus 8 among Iranian Patients Infected with HIV. Iran J Public Health (2016) 0.75
Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons. Infect Agent Cancer (2016) 0.75
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science (1986) 8.15
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med (1996) 7.28
Association of cancer with AIDS-related immunosuppression in adults. JAMA (2001) 6.80
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med (1995) 5.22
Postinfectious fatigue: prospective cohort study in primary care. Lancet (1995) 5.21
Population based study of fatigue and psychological distress. BMJ (1994) 5.15
Determinants of HIV-1 shedding in the genital tract of women. Lancet (2001) 5.10
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
Reduced lymphocyte transformation due to a plasma factor in patients with active syphilis. Lancet (1969) 4.92
The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology (2008) 4.78
Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet (1984) 4.68
Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA (1985) 4.26
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med (2001) 4.26
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med (1999) 4.12
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst (2000) 3.77
Nucleotide sequence and predicted amino acid sequence of a protein encoded in a small herpes simplex virus DNA fragment capable of trans-inducing alpha genes. Proc Natl Acad Sci U S A (1985) 3.75
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect Dis (2006) 3.59
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (1989) 3.54
Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol (1998) 3.54
Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA (1996) 3.50
A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med (1992) 3.42
Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science (1986) 3.31
Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma. J Infect Dis (2000) 3.20
A.E. Bennett Research Award. Developmental traumatology. Part I: Biological stress systems. Biol Psychiatry (1999) 3.05
Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med (1991) 3.02
Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis (2001) 2.95
Cattle as a possible source of verocytotoxin-producing Escherichia coli O157 infections in man. Epidemiol Infect (1993) 2.94
In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). J Exp Med (1988) 2.81
Human factors and cardiac surgery: a multicenter study. J Thorac Cardiovasc Surg (2000) 2.77
The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology (2007) 2.76
Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet (1995) 2.74
Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med (1999) 2.63
Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J Virol (1997) 2.59
Natural history of HIV-1 cell-free viremia. JAMA (1995) 2.58
Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J Virol (1997) 2.57
Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA (1998) 2.55
HBLV (or HHV-6) in human cell lines. Nature (1987) 2.53
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang (2005) 2.47
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
A comparison of immunomagnetic separation and direct culture for the isolation of verocytotoxin-producing Escherichia coli O157 from bovine faeces. J Med Microbiol (1994) 2.46
Infection by TRIC agent and other members of the Bedsonia group; with a note on Reiter's disease. II. Ophthalmia neonatorum due to TRIC agent. Trans Ophthalmol Soc U K (1966) 2.46
Genetic polymorphism in CX3CR1 and risk of HIV disease. Science (2000) 2.38
Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med (1998) 2.38
Why is the infectious stage of syphilis prolonged? Br J Vener Dis (1974) 2.36
Therapy may explain recent deficits in AIDS incidence. J Acquir Immune Defic Syndr (1990) 2.35
Appendectomy and subsequent risk of inflammatory bowel diseases. Surgery (2001) 2.35
Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. Arch Intern Med (1996) 2.33
Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS) Hepatology (2000) 2.30
Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology (1987) 2.30
Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr (1999) 2.28
Antibody assays for varicella-zoster virus: comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination, and complement fixation. J Clin Microbiol (1978) 2.26
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A (2000) 2.24
Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. Ann Intern Med (1987) 2.24
Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer (1989) 2.24
Genomic analysis of the human B-lymphotropic virus (HBLV). Science (1986) 2.23
Knowledge of HIV/AIDS transmission and screening in United States blood donors. Transfusion (2001) 2.20
Motivations to donate blood: demographic comparisons. Transfusion (2002) 2.20
Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS (1997) 2.20
Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis (2000) 2.18
First year donation patterns predict long-term commitment for first-time donors. Vox Sang (2005) 2.18
A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol (1999) 2.16
Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J Virol (1995) 2.15
Bacillary angiomatosis and bacillary splenitis in immunocompetent adults. Ann Intern Med (1993) 2.14
Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature (1997) 2.10
Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virol (1999) 2.09
Antigen requirements, sensitivity, and specificity of enzyme immunoassays for measles and rubella viral antibodies. J Clin Microbiol (1979) 2.07
Peak exercise cardiac power output; a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure. Eur Heart J (2001) 2.07
Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. Ann Intern Med (1986) 2.06
The potential impact of incentives on future blood donation behavior. Transfusion (2001) 2.05
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol (1999) 2.03
The impact of male-to-male sexual experience on risk profiles of blood donors. Transfusion (2005) 2.02
Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion (2003) 2.00
Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis (1982) 1.98
Clinical pharmacy interventions by community pharmacists during the dispensing process. Br J Clin Pharmacol (1999) 1.97
Should exercise blood pressure be measured in clinical practice? J Hypertens (1998) 1.97
New antibody in early syphilis. Lancet (1970) 1.97
Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science (1988) 1.97
Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature (1989) 1.96
Human ehrlichiosis in the UK. Lancet (1995) 1.96
Relation of TRIC agent to "non-specific genital infection". Br J Vener Dis (1966) 1.94
Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood (1998) 1.93
Genetic and biochemical approach for characterization of resistance to Bacillus thuringiensis toxin Cry1Ac in a field population of the diamondback moth, Plutella xylostella. Appl Environ Microbiol (2000) 1.92